Skip to content
Company Analysis

Aquestive Therapeutics, Inc. AQST

A comprehensive view of key metrics, scores, and financial health for Aquestive Therapeutics, Inc.

Overview of Aquestive Therapeutics, Inc.

AQST NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Aquestive Therapeutics, Inc. (AQST), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $3.77, about 0.0% overvalued vs fair value, -38.5% 1Y return, ranked 576/1145 in sector.
Metrics Rev Growth -22.6% ROE 178.6% Gross Margin 58.4%
USD 3.77
-3.08%
(Delayed)
• Vol 90d: 52.3%
52-Week Range
Market Cap
$473.18M
Enterprise Value
$425.37M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 88%
Confidence: 91%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.aquestive.com
HQ Warren, NJ
Employees 142
Fiscal year Dec 31

Next Events

Earnings Nov 3 Call: Nov 4

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $3.77

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$44.5M
-22.6%%
Gross Profit
$26.0M
-34.5%%
R&D Expense
$17.2M
-15.2%%
Operating Income (EBIT)
-$66.7M
-144%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
38.6%
Fair

High R&D intensity - heavy pipeline investment

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Aquestive Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
27
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.68), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 1.2th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 17.5th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
27
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing AQST's balance between Growth (22.8%), Profitability (18.4%), and Safety (58.8%). Growth 23% Safety 59% Profitability 18%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

20th percentile vs peers
20
Key Signals
Revenue CAGR 3Y -2.2% 30p Rev Growth YoY -22.6% 17p EPS Growth YoY -54.0% 17p TSR -76.8% 8p
Strengths
  • Debt/FCF Ratio in top 20% of peers (-70.8%, 83th percentile)
  • Strong liquidity position vs peers
Risks
  • Growth in bottom 20% of peers (percentile: 20)
  • Rev Growth YoY in bottom 20% of peers (-22.6%)
  • EPS Growth YoY in bottom 20% of peers (-54.0%)

Profitability

16th percentile vs peers
16
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

51th percentile vs peers
52
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Aquestive Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.15
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000